CELL INTELLIGENCE · 肿瘤细胞治疗研究

下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

双特异性抗体在多发性骨髓瘤中的演进

The evolution of bispecific antibodies in multiple myeloma.

肾脏病学趋势：从虚无主义到抗体介导排斥反应的靶向治疗

Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection.

寻找诱导肾移植抗体介导排斥反应中有效浆细胞清除所需的达雷妥尤单抗最低剂量：一例病例报告

Searching for the minimum required dose of daratumumab to induce effective plasma cell depletion in antibody-mediated rejection of the kidney graft: a

使用无柱流式装置富集 CD4(+) 和 CD8(+) T 淋巴细胞用于临床细胞生产

Enrichment of CD4(+) and CD8(+) T lymphocytes with a column-free flow-based device for clinical cell manufacturing.

CD19/CD20/BCMA CAR-T（CD19CAR-T 细胞）治疗多发性骨髓瘤：早期 I 期临床试验

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma

这是一项早期 I 期注册临床试验，评估 CD19CAR-T 细胞治疗多发性骨髓瘤的安全性、可行性及初步疗效。当前状态：招募中。计划入组 12 例。试验地点：中国 · 上海（共 1 个中心，其中中国 1 个）。登记号：NCT06732232。

解析 MYC 介导的对传统抗体与 T 细胞重定向治疗性抗体的逃逸机制

Delineating MYC-Mediated Escape Mechanisms from Conventional and T Cell-Redirecting Therapeutic Antibodies.

2023 年美国 FDA 批准的治疗性抗体的结构与功能

Structure and function of therapeutic antibodies approved by the US FDA in 2023.

多剂 SARS-CoV-2 疫苗在接受 CAR-T 细胞治疗的 B 细胞血液系统恶性肿瘤患者中的疗效：一项当代队列分析

Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A C

血液肿瘤双特异性单克隆抗体研究进展

Update on bi-specific monoclonal antibodies for blood cancers.